PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
GSK vs. SHEL
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between GSK and SHEL is 0.38, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.4

Performance

GSK vs. SHEL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in GlaxoSmithKline plc (GSK) and Shell plc (SHEL). The values are adjusted to include any dividend payments, if applicable.

-20.00%-15.00%-10.00%-5.00%0.00%5.00%10.00%15.00%AugustSeptemberOctoberNovemberDecember2025
-13.26%
-5.80%
GSK
SHEL

Key characteristics

Sharpe Ratio

GSK:

-0.57

SHEL:

0.82

Sortino Ratio

GSK:

-0.68

SHEL:

1.17

Omega Ratio

GSK:

0.92

SHEL:

1.16

Calmar Ratio

GSK:

-0.44

SHEL:

0.85

Martin Ratio

GSK:

-0.93

SHEL:

2.23

Ulcer Index

GSK:

13.53%

SHEL:

6.20%

Daily Std Dev

GSK:

22.07%

SHEL:

16.89%

Max Drawdown

GSK:

-55.21%

SHEL:

-67.46%

Current Drawdown

GSK:

-25.45%

SHEL:

-7.73%

Fundamentals

Market Cap

GSK:

$68.21B

SHEL:

$202.20B

EPS

GSK:

$1.48

SHEL:

$4.94

PE Ratio

GSK:

22.59

SHEL:

13.51

PEG Ratio

GSK:

0.77

SHEL:

2.56

Total Revenue (TTM)

GSK:

$23.26B

SHEL:

$218.03B

Gross Profit (TTM)

GSK:

$16.84B

SHEL:

$37.19B

EBITDA (TTM)

GSK:

$6.82B

SHEL:

$46.39B

Returns By Period

In the year-to-date period, GSK achieves a -1.15% return, which is significantly lower than SHEL's 6.50% return. Over the past 10 years, GSK has underperformed SHEL with an annualized return of 1.93%, while SHEL has yielded a comparatively higher 5.34% annualized return.


GSK

YTD

-1.15%

1M

0.00%

6M

-13.26%

1Y

-12.42%

5Y*

-3.00%

10Y*

1.93%

SHEL

YTD

6.50%

1M

10.04%

6M

-5.79%

1Y

13.22%

5Y*

6.93%

10Y*

5.34%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

GSK vs. SHEL — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GSK
The Risk-Adjusted Performance Rank of GSK is 1919
Overall Rank
The Sharpe Ratio Rank of GSK is 1717
Sharpe Ratio Rank
The Sortino Ratio Rank of GSK is 1616
Sortino Ratio Rank
The Omega Ratio Rank of GSK is 1717
Omega Ratio Rank
The Calmar Ratio Rank of GSK is 2020
Calmar Ratio Rank
The Martin Ratio Rank of GSK is 2424
Martin Ratio Rank

SHEL
The Risk-Adjusted Performance Rank of SHEL is 6969
Overall Rank
The Sharpe Ratio Rank of SHEL is 7373
Sharpe Ratio Rank
The Sortino Ratio Rank of SHEL is 6363
Sortino Ratio Rank
The Omega Ratio Rank of SHEL is 6363
Omega Ratio Rank
The Calmar Ratio Rank of SHEL is 7676
Calmar Ratio Rank
The Martin Ratio Rank of SHEL is 6868
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

GSK vs. SHEL - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Shell plc (SHEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for GSK, currently valued at -0.57, compared to the broader market-2.000.002.004.00-0.570.82
The chart of Sortino ratio for GSK, currently valued at -0.68, compared to the broader market-4.00-2.000.002.004.00-0.681.17
The chart of Omega ratio for GSK, currently valued at 0.92, compared to the broader market0.501.001.502.000.921.16
The chart of Calmar ratio for GSK, currently valued at -0.44, compared to the broader market0.002.004.006.00-0.440.85
The chart of Martin ratio for GSK, currently valued at -0.93, compared to the broader market-10.000.0010.0020.0030.00-0.932.23
GSK
SHEL

The current GSK Sharpe Ratio is -0.57, which is lower than the SHEL Sharpe Ratio of 0.82. The chart below compares the historical Sharpe Ratios of GSK and SHEL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.50AugustSeptemberOctoberNovemberDecember2025
-0.57
0.82
GSK
SHEL

Dividends

GSK vs. SHEL - Dividend Comparison

GSK's dividend yield for the trailing twelve months is around 4.66%, more than SHEL's 4.12% yield.


TTM20242023202220212020201920182017201620152014
GSK
GlaxoSmithKline plc
4.66%4.60%3.75%4.78%4.92%5.49%4.28%5.55%5.72%7.06%5.96%6.09%
SHEL
Shell plc
4.12%4.39%3.76%3.48%3.78%5.44%6.14%5.48%4.79%5.88%6.98%4.72%

Drawdowns

GSK vs. SHEL - Drawdown Comparison

The maximum GSK drawdown since its inception was -55.21%, smaller than the maximum SHEL drawdown of -67.46%. Use the drawdown chart below to compare losses from any high point for GSK and SHEL. For additional features, visit the drawdowns tool.


-30.00%-25.00%-20.00%-15.00%-10.00%-5.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-25.45%
-7.73%
GSK
SHEL

Volatility

GSK vs. SHEL - Volatility Comparison

GlaxoSmithKline plc (GSK) has a higher volatility of 5.97% compared to Shell plc (SHEL) at 4.63%. This indicates that GSK's price experiences larger fluctuations and is considered to be riskier than SHEL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


3.00%4.00%5.00%6.00%7.00%8.00%9.00%AugustSeptemberOctoberNovemberDecember2025
5.97%
4.63%
GSK
SHEL

Financials

GSK vs. SHEL - Financials Comparison

This section allows you to compare key financial metrics between GlaxoSmithKline plc and Shell plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab